Theratechnologies (TH) Price & Analysis

Compare

101 Followers

TH Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.59 - $4.73

Previous CloseN/A

Volume38.24K

Average Volume (3M)21.68K

Market Cap

$205.53M

Enterprise Value$225.52M

Total Cash (Recent Filing)$9.92M

Total Debt (Recent Filing)$43.62M

Price to Earnings (P/E)―

Beta2.01

Next Earnings

Oct 09, 2025

EPS Estimate

0.05

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.13

Shares Outstanding45,980,020

10 Day Avg. Volume32,121

30 Day Avg. Volume21,683

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap1.10

Enterprise Value/Revenue2.67

Enterprise Value/Gross Profit3.44

Enterprise Value/Ebitda110.12

Forecast

1Y Price Target

$4.50

Price Target Upside0.76% Upside

Rating ConsensusHold

Number of Analyst Covering0

Bulls Say, Bears Say

Bulls Say

Acquisition PremiumThe acquisition offer from Future Pak represents a 126% premium to the closing price before the announcement, indicating a significant value proposition for shareholders.

Long-term Product SecurityPatent protection for EGRIFTA WR extends into 2033, providing long-term security for the product.

Product Launch ImpactThe launch of EGRIFTA WR is expected to allow the company to increase sales growth and maintain positive momentum.

Bears Say

Acquisition SkepticismThere is skepticism about the success of Future Pak's acquisition offer, and it is likely to fall through despite recognizing the value of the EGRIFTA franchise.

Financial Performance Challenges2Q25 fully adjusted EPS of ($0.09) missed consensus expectations of ($0.01), which may indicate financial challenges.

Revenue DisruptionAn expected one-time reduction in revenue due to a supply disruption resulted in a $10M — $12M decrease for FY25.

Theratechnologies News

Theratechnologies shareholders approve proposed acquisition by Future Pak

Theratechnologies (THTX) announced that its shareholders have approved the previously announced plan of arrangement under Chapter XVI –...

25d ago

THTX

Theratechnologies Completes Acquisition by Future Pak

Theratechnologies ( ($TSE:TH) ) has provided an announcement. Theratechnologies has completed its acquisition by Future Pak, with all...

12d ago

THTX

Theratechnologies Receives Court Approval for Acquisition by Future Pak

Theratechnologies ( ($TSE:TH) ) has shared an update. Theratechnologies has received final court approval for its acquisition by...

20d ago

THTX

Theratechnologies Shareholders Approve Acquisition by Future Pak Affiliate

Theratechnologies ( ($TSE:TH) ) just unveiled an announcement. Theratechnologies Inc. has announced that its shareholders have overwhelmingly approved...

25d ago

THTX

Theratechnologies Launches EGRIFTA WR™ for HIV-Related Lipodystrophy

Theratechnologies ( ($TSE:TH) ) has issued an update. Theratechnologies has announced the availability of EGRIFTA WR™, a new...

1M ago

THTX

Theratechnologies announces availability of EGRIFTA WR

Theratechnologies (THTX) announced the availability of EGRIFTA WR for injection for the reduction of excess abdominal fat in...

1M ago

THTX

Theratechnologies Gains Support for Future Pak Acquisition

An update from Theratechnologies ( ($TSE:TH) ) is now available. Theratechnologies Inc. announced that independent proxy advisory firms...

1M ago

THTX

Theratechnologies says ISS, Glass Lewis recommend vote ‘FOR’ Future Pak plan

Theratechnologies (THTX) announces that two leading independent proxy advisory firms, Institutional Shareholders Services and Glass Lewis & Co.,...

1M ago

THTX

Theratechnologies Announces Acquisition by CB Biotechnology with Significant Shareholder Premium

Theratechnologies ( ($TSE:TH) ) just unveiled an update. Theratechnologies Inc. has announced the filing of special meeting materials...

2M ago

THTX

Theratechnologies receives interim order in acquisition by CB Biotechnology

Theratechnologies (THTX) has filed and is in the process of mailing the management proxy circular and related materials...

2M ago

THTX

Theratechnologies’ Ibalizumab Study: A Potential Game-Changer for Multidrug-Resistant HIV

Theratechnologies (($THTX)), Theratechnologies (TH) (($TSE:TH)) announced an update on their ongoing clinical study. Study Overview: Theratechnologies is conducting...

2M ago

THTX

Theratechnologies Announces Special Shareholder Meeting for September 2025

Theratechnologies ( ($TSE:TH) ) just unveiled an update. Theratechnologies Inc. announced a special meeting of shareholders scheduled for...

3M ago

THTX

Theratechnologies Announces Acquisition Agreement with CB Biotechnology

Theratechnologies ( ($TSE:TH) ) has shared an announcement. On July 2, 2025, Theratechnologies Inc. announced a binding agreement...

3M ago

THTX

Theratechnologies Reports Q2 2025 Earnings and Acquisition

Theratechnologies ( ($THTX) ) has released its Q2 earnings. Here is a breakdown of the information Theratechnologies presented...

3M ago

THTX

TH FAQ

What was Theratechnologies’s price range in the past 12 months?

Theratechnologies lowest stock price was $1.59 and its highest was $4.73 in the past 12 months.

What is Theratechnologies’s market cap?

Theratechnologies’s market cap is $205.53M.

When is Theratechnologies’s upcoming earnings report date?

Theratechnologies’s upcoming earnings report date is Oct 09, 2025 which is in 2 days.

How were Theratechnologies’s earnings last quarter?

Theratechnologies released its earnings results on Jul 09, 2025. The company reported -$0.127 earnings per share for the quarter, missing the consensus estimate of -$0.021 by -$0.106.

Is Theratechnologies overvalued?

According to Wall Street analysts Theratechnologies’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Theratechnologies pay dividends?

Theratechnologies does not currently pay dividends.

What is Theratechnologies’s EPS estimate?

Theratechnologies’s EPS estimate is 0.05.

How many shares outstanding does Theratechnologies have?

Theratechnologies has 45,980,020 shares outstanding.

What happened to Theratechnologies’s price movement after its last earnings report?

Theratechnologies reported an EPS of -$0.127 in its last earnings report, missing expectations of -$0.021. Following the earnings report the stock price went down -0.116%.

Which hedge fund is a major shareholder of Theratechnologies?

Currently, no hedge funds are holding shares in TSE:TH

Theratechnologies Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-26.98%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Theratechnologies

Theratechnologies Inc. is a Canadian biopharmaceutical company focused on developing and commercializing innovative therapies for patients with serious medical conditions. The company primarily operates in the biotechnology sector, specializing in the research and development of treatments for metabolic and endocrine disorders, with a particular emphasis on human immunodeficiency virus (HIV) and growth hormone deficiencies. Its core product, Trogarzo (ibalizumab-uiyk), is a monoclonal antibody approved for the treatment of HIV-1 in heavily treatment-experienced patients, highlighting the company's commitment to addressing unmet medical needs in complex patient populations.